Analyzing Tandem Diabetes Care (NASDAQ:TNDM) & SeaStar Medical (NASDAQ:ICU)

Tandem Diabetes Care (NASDAQ:TNDM) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Earnings and Valuation

This table compares Tandem Diabetes Care and SeaStar Medical’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$747.72 million	3.70	-$222.61 million	($2.17)	-19.74
SeaStar Medical	N/A	N/A	-$26.23 million	($25.00)	-0.16

SeaStar Medical has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tandem Diabetes Care has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.03, meaning that its stock price is 203% less volatile than the S&P 500.

Institutional & Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. 2.2% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 3.0% of SeaStar Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Tandem Diabetes Care and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-18.37%	-34.38%	-10.91%
SeaStar Medical	N/A	N/A	-725.48%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tandem Diabetes Care and SeaStar Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	0	1	12	0	2.92
SeaStar Medical	0	0	0	0	N/A

Tandem Diabetes Care presently has a consensus price target of $51.25, suggesting a potential upside of 19.66%. Given Tandem Diabetes Care’s higher possible upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than SeaStar Medical.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.